Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
Lewden C, Raffi F, Cuzin L, Cailleton V, Vildé JL, Chêne G, Allavena C, Salamon R, Leport C. Lewden C, et al. Among authors: allavena c. J Infect Dis. 2002 Sep 1;186(5):710-4. doi: 10.1086/342047. Epub 2002 Jul 29. J Infect Dis. 2002. PMID: 12195361 Clinical Trial.
[Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Brunet-François C, Taieb A, Masquelier B, Le Moing V, Lewden C, Dellamonica P, Cuzin L, Allavena C, Spire B, Chêne G, Raffi F; Groupe d'Etude Aproco-Copilote (ANRS C08). Brunet-François C, et al. Among authors: allavena c. Med Mal Infect. 2007 Mar;37(3):172-7. doi: 10.1016/j.medmal.2006.11.003. Epub 2007 Jan 17. Med Mal Infect. 2007. PMID: 17239554 French.
Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Grabar S, et al. Among authors: allavena c. HIV Med. 2008 Apr;9(4):246-56. doi: 10.1111/j.1468-1293.2008.00554.x. HIV Med. 2008. PMID: 18366449 Free article.
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C; NoNuke ANRS 108 Study Team. Valantin MA, et al. Among authors: allavena c. HIV Med. 2008 Oct;9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x. Epub 2008 Jul 8. HIV Med. 2008. PMID: 18624724 Free article. Clinical Trial.
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM. Rey D, et al. Among authors: allavena c. J Antimicrob Chemother. 2009 Feb;63(2):380-8. doi: 10.1093/jac/dkn471. Epub 2008 Nov 25. J Antimicrob Chemother. 2009. PMID: 19036752 Clinical Trial.
A large French prospective cohort of HIV-infected patients: the Nadis Cohort.
Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, El Guedj M, de la Tribonnière X, Valantin MA, Dellamonica P; Nadis Group. Pugliese P, et al. Among authors: allavena c. HIV Med. 2009 Sep;10(8):504-11. doi: 10.1111/j.1468-1293.2009.00719.x. Epub 2009 May 19. HIV Med. 2009. PMID: 19486189 Free article.
239 results